Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Use of different combination diphtheria-tetanus-acellular pertussis vaccines does not increase risk of 30-day infant mortality. A population-based linkage cohort study using administrative data from the Australian Childhood Immunisation Register and the National Death Index|
|Citation:||Vaccine, 2019; 37(2):280-288|
|Katherine M. Duszynski, Nicole L. Pratt, John W. Lynch, Jesia G. Berry, Michael S. Gold, on behalf of the Vaccine Assessment Using Linked Data(VALiD) Working Group|
|Abstract:||Objective: To determine whether differences in combination DTaP vaccine types at 2, 4 and 6 months of age were associated with mortality (all-cause or non-specific), within 30 days of vaccination. Design: Observational nationwide cohort study. Setting: Linked population data from the Australian Childhood Immunisation Register and National Death Index. Participants: Australian infants administered a combination trivalent, quadrivalent or hexavalent DTaP vaccine (DTaP types) between January 1999 and December 2010 at 2, 4 and 6 months as part of the primary vaccination series. The study population included 2.9, 2.6, & 2.3 million children in the 2, 4 and 6 month vaccine cohorts, respectively. Main Outcome Measures: Infants were evaluated for the primary outcome of all-cause mortality within 30 days. A secondary outcome was non-specific mortality (unknown cause of death) within 30 days of vaccination. Non-specific mortality was defined as underlying or other cause of death codes, R95 'Sudden infant death syndrome', R96 'Other sudden death, cause unknown', R98 'Unattended death', R99 'Other ill-defined and unspecified cause of mortality' or where no cause of death was recorded. Results: The rate of 30 day all-cause mortality was low and declined from 127.4 to 59.3 deaths per 100,000 person-years between 2 and 6 month cohorts. When compared with trivalent DTaP vaccines, no elevated risk in all-cause or non-specific mortality was seen with any quadrivalent or hexavalent DTaP vaccines, for any cohort. Conclusion: Use of routine DTaP combination vaccines with differing disease antigens administered during the first six months of life is not associated with infant mortality.|
|Keywords:||Vaccine Assessment Using Linked Data (VALiD) Working Group|
|Rights:||© 2018 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.